

ADNI Conference Call
30 January 2007

Present: Laurel Beckett, Danielle Harvey, Brandon Whitcher, Qian Weng, Monica, Paul Maguire.

Monica reported that LONI is still working on search engine interface for the clinical data to be searchable. She will ask them for an update and fill us in at next meeting. The different imaging labs are sending data to Sarah and Mike. Danielle has been getting information and apparently that is going directly to Sarah and Mike as well. Anders has sent a long list of measures to Anthony and Danielle. It's not clear whether PET labs are in touch yet but Danielle will get them to get in touch. The PET labs have come up with some material in the last week.

Danielle has updated the analytic plan including the comments from Leon and others who have read it. The PET group wanted a table corresponding to the MRI data, so they have sent a list of summary measures that they were interested in. Danielle will add the correlations she anticipates based on their list and run the table by Bill Jagust. She will send this version out by end of the week, she expects. The PET group is still discussing topics on their analyses. PET group is increasing to two calls per month after February and will discuss each lab separately. So far they have done the SPM lab, and he brought up a lot of issues to think about. One thing relevant to discussions for our group is that a lot of the analysis plan is set up to use random effects models, with all three time points together. The PET folks raised the question of whether industry would be interested in comparisons of 2 time points vs. 3 time points. So they are planning to do 0 vs .6 month, 0 vs. 12 month, and then all 3 time points. They would like to compare all three types of analyses. We can add a secondary analysis discussing two-time point analysis.

Paul commented that he has recently read a paper by Schott using a data set with lots of data and that they note that the two-point designs lose the ability to estimate and separate within and between-person variance components. He encourages the stat group to do as much as possible of those analyses here to allow for comparison. Danielle noted that the voxel-based groups will do some of the analyses at their own lab.

Paul raises the question of trying to separate the exploratory approaches versus the a priori choices. His e-mail suggested clarifying the distinction. Danielle notes that Mike has emphasized to the voxel-based groups that they need to have some a priori hypotheses too, about specific regions or focused areas. The groups generating numeric summaries have already defined specific regions. We will work to make that clearer in the document. This is important for the FDA meeting in early April. Laurel will be speaking there and will try to make all of these concerns as clear as possible.

Danielle asked whether the training set/ test set designation has been incorporated. She and Mike have been working on including Qian's work. Danielle will follow up and e-mail Mike to make this happen before the data become available. It's possible that the

data will need to be available to voxel-based labs even earlier. Danielle will follow up with Karen.

Our next call is in two weeks, on 13 February.